Antisense Oligonucleotide Modulation of GRN for Brain Progranulin Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's disease do not effectively target progranulin augmentation in the brain, which is crucial for therapeutic intervention.
Innovation Solution
Administration of antisense oligonucleotides (ASOs) complementary to progranulin pre-mRNAs to modulate GRN expression or activity, including specific sequences and modifications to enhance binding and stability, thereby increasing progranulin levels in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are administered to increase progranulin expression, then therapeutic effectiveness improves, but delivery challenges and complexity increase
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to progranulin pre-mRNA to modulate expression. These ASOs act as mediators between the therapeutic goal (increasing progranulin) and the biological target (pre-mRNA), enabling indirect therapeutic effect while navigating delivery challenges through various chemical modifications and formulation strategies
Solution Approach 2:
The patent employs extensive chemical modifications to the oligonucleotide structure (2'-O-methyl, 2'-fluoro, phosphorothioate backbones, LNA modifications) to change physical and chemical parameters such as stability, binding affinity, and cellular uptake. These parameter changes enable the ASOs to withstand degradation and effectively reach their target in the brain
2Quantity of substance
If progranulin levels are increased in the brain, then therapeutic benefit is achieved, but selective delivery to the brain becomes more difficult
Solution Approach 1:
The patent achieves local quality by designing ASOs with specific chemical properties (charge, hydrophobicity, size) that enable selective accumulation in brain tissue. The modified oligonucleotides exhibit different distribution patterns compared to unmodified versions, concentrating therapeutic effect in the target organ (brain) while minimizing systemic exposure
Solution Approach 2:
The ASOs serve as intermediaries that can be delivered systemically but then selectively act in the brain due to their molecular properties. They mediate between systemic administration and localized brain effect, utilizing biological barriers and transport mechanisms to achieve selective delivery
3Productivity
If ASO sequences are optimized for binding affinity, then expression modulation efficiency improves, but specificity and off-target effects become concerns
Solution Approach 1:
The patent applies local quality by designing ASOs with specific binding characteristics at different regions of the pre-mRNA target. By selecting specific binding sites and optimizing local sequence complementarity, the ASOs achieve high affinity for the intended target while maintaining specificity through careful sequence selection and chemical modification patterns
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASOs effectively increase progranulin expression or activity, providing a therapeutic approach to treat neurodegenerative diseases by targeting GRN mRNA in the brain.
Implementation Method 1
an antisense oligonucleotide (ASO) complementary to progranulin pre-mRNAs
Data Source
AI summary
Described herein are methods and compositions related to the modulation of progranulin expression or activity in the brain for the treatment of neurodegenerative diseases.